nav-left cat-right
cat-right

Higher bleeding risk seen in J&J, Bayer clot ...

A blood clot preventer from Johnson & Johnson and Bayer caused a surprisingly high rate of bleeding in a trial of patients with acute illnesses, representing a significant setback for the drugmakers. Bayer AG shares fell 3.6 percent in Frankfurt on Tuesday. J&J slid 0.6 percent on the New York Stock Exchange. Industry analysts had predicted the trial of the drug rivaroxaban, if successful, would create a...

Trana Discovery’s HIV Assay Finds Compounds ...

Trana Discovery, Inc., an infectious disease drug discovery technology company, today announced that a recent study sponsored by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health, affirms that bioactive compounds selected using the Trana HIV 201 High-Throughput (HTS) Assay inhibit viral strains demonstrating resistance to non-nucleoside reverse transcriptase inhibitors...

Could Starfish Inspire New Cure for Inflammation?

Lurking in the seas of Scotland is an unlikely candidate for a medical breakthrough. But scientists believe the starfish could hold the key to finding a new treatment for inflammatory conditions such as asthma, hay fever and arthritis. The species they are interested in is the spiny starfish (Marthasterias glacialis), and in particular the slimy goo that covers its body. The team says that chemicals in this coating could...

Ion Channels Open Doors to New Drugs Increased R&#...

Nina Flanagan Ion channels make good drug targets—they reside on the cell surface and are fast switching mechanisms. They act like cell transistors, controlling many cell processes. There are close to 500 types of ion channels, yet many remain undiscovered. This was mainly attributed to technology restraints, however, with the recent introduction of HT patch clamping, as well as new assays that facilitate...

Rising to the Challenge in R&D

There has long been a consensus within the pharmaceutical industry that innovation and productivity is a critical focus. Nevertheless, the number of new molecular entities (NMEs) approved each year by FDA shows that industry has not been improving its output, despite progress in development and implementation of enabling technologies. Over the past 20 years there has actually been a decline in NMEs approved by FDA....

AIDS Drugs – HIV

In the early 1980s, the human immunodeficiency virus (HIV) was identi­fied as the etiologic agent of acquired immune deficiency syndrome (AIDS). More than 3 million people worldwide died from HIV/AIDS in 2003, according to a July 2004 United Nations report. During the same period, about 5 million people contracted the human immunodeficiency virus, bringing the total number of people living with HIV worldwide to 38 million....
Page 4 of 512345